Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hecolin Phase 3 Trial
NCT01014845Phase 3Completed
- Sponsor
- Xiamen University
- Start
- Aug 2007
- Primary completion
- Oct 2017
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 3 trial of HEV 239 in hepatitis E (HEV), sponsored by Xiamen University. Started Aug 2007; status: completed.
02
Drugs
HEV 239
03
Conditions
hepatitis E (HEV)
Beyond the preview
Go deeper on NCT01014845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01014845.